Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer ...
Product Candidates to Incorporate Chimeric Antigen Receptor Construct Optimized for NK Cell Persistence and Anti-Tumor Activity Master Pluripotent Cell Lines Engineered with Chimeric Antigen Receptors to be used for Off-the-Shelf Targeted Natural Killer …